These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29609014)

  • 1. Biologics for pityriasis rubra pilaris treatment: A review of the literature.
    Napolitano M; Abeni D; Didona B
    J Am Acad Dermatol; 2018 Aug; 79(2):353-359.e11. PubMed ID: 29609014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review [Formula: see text].
    Naidoo A; Sibbald C; Fleming PJ; Piguet V
    J Cutan Med Surg; 2020; 24(1):73-78. PubMed ID: 31691587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
    Maloney NJ; Hisaw LD; Worswick S
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy.
    Müller H; Gattringer C; Zelger B; Höpfl R; Eisendle K
    J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S65-70. PubMed ID: 19119128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC
    Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists.
    Petrof G; Almaani N; Archer CB; Griffiths WA; Smith CH
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e131-5. PubMed ID: 22324561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.
    Bonomo L; Levitt JO
    Cutis; 2018 May; 101(5):367-369. PubMed ID: 29894526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series.
    Garcovich S; Di Giampetruzzi AR; Antonelli G; Garcovich A; Didona B
    J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):881-4. PubMed ID: 20002243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pityriasis rubra pilaris: a case series of 28 patients.
    Kromer C; Lippert U; Schön MP; Mössner R
    Eur J Dermatol; 2020 Oct; 30(5):569-579. PubMed ID: 33021474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pityriasis rubra pilaris type I: a systematic review.
    Engelmann C; Elsner P; Miguel D
    Eur J Dermatol; 2019 Oct; 29(5):524-537. PubMed ID: 31789274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy.
    Zhang YH; Zhou Y; Ball N; Su MW; Xu JH; Zheng ZZ
    J Cutan Med Surg; 2010; 14(4):185-8. PubMed ID: 20642989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of pityriasis rubra pilaris with adalimumab - case report.
    Bravo EA; Carrion L; Paucar SM; Mendoza R; Rivera C
    Dermatol Online J; 2014 Apr; 20(4):22374. PubMed ID: 24746310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?
    Ivanova K; Itin P; Haeusermann P
    Dermatology; 2012; 224(2):120-5. PubMed ID: 22508269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition.
    Adnot-Desanlis L; Antonicelli F; Tabary T; Bernard P; Reguiaï Z
    Dermatology; 2013; 226(1):41-6. PubMed ID: 23548788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review.
    Maloney NJ; Hisaw LD; Worswick S
    J Am Acad Dermatol; 2018 Sep; 79(3):585-587. PubMed ID: 29518460
    [No Abstract]   [Full Text] [Related]  

  • 16. Systemic therapies of pityriasis rubra pilaris: a systematic review.
    Kromer C; Sabat R; Celis D; Mössner R
    J Dtsch Dermatol Ges; 2019 Mar; 17(3):243-259. PubMed ID: 30520557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases.
    Napolitano M; Lembo L; Fania L; Abeni D; Didona D; Didona B
    J Dermatol; 2018 Feb; 45(2):202-206. PubMed ID: 29080273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
    Gómez M; Ruelas ME; Welsh O; Arcaute HD; Ocampo-Candiani J
    J Drugs Dermatol; 2007 Mar; 6(3):337-9. PubMed ID: 17373198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40.
    Matsuda T; Yamazaki F; Ueda-Hayakawa I; Kambe N; Okamoto H
    J Dermatol; 2019 Jan; 46(1):70-72. PubMed ID: 30506728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review.
    Camela E; Miano C; Di Caterino P; Lo Presti M; De Fata Salvatores G; Fabbrocini G; Megna M
    Dermatol Ther; 2020 Nov; 33(6):e14223. PubMed ID: 32820849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.